Support for possible clinical translation of PARP inhibitors in stroke is favored by (1) positive effects on infarct volume reported by 13 independent laboratories with 9 different drugs, (2) efficacy in both transient and permanent focal ischemia, (3) a therapeutic window in the range of 4–6 h for infarct volume reduction, and (4) availability of PARP inhibitors with a good safety profile with month-long administration in human oncology trials. This evidence concerns the gene PARP1 and Stroke.